Drugs |
Specialties
| Education
| Points

Hong Kong
Search
Sign In

Respirology Search

Respirology

Specialties

Multidisciplinary
Cardiology
Dermatology
Endocrinology
Gastroenterology
Hepatology
Infectious Diseases
Neurology
Obstetrics & Gynaecology
Oncology
Ophthalmology
Paediatrics
Psychiatry
Respirology
Rheumatology
Urology
Pharmacy

Country

China
Hong Kong
India
Indonesia
Malaysia
Myanmar
Philippines
Singapore
Thailand
Vietnam
Australia
Korea
New Zealand

Search

Account

Manage Account
Change Password
Points
Sign Out

Respirology

Medical News
Case Studies
Clinical Review
Practice Insights
Drug Updates

Special Reports

Specialties

Multidisciplinary
Cardiology
Dermatology
Endocrinology
Gastroenterology
Hepatology
Infectious Diseases
Neurology
Obstetrics & Gynaecology
Oncology
Ophthalmology
Paediatrics
Psychiatry
Respirology
Rheumatology
Urology
Pharmacy

China
Hong Kong
India
Indonesia
Malaysia
Myanmar
Philippines
Singapore
Thailand
Vietnam
Australia
Korea
New Zealand

Drugs |
Specialties
| Education
| Points

Exclusive offer for doctors!

Register for a MIMS account and receive free medical publications worth $768 a year.

Continue with Google

OR

Already a member? Sign in

Respirology

Home News Diseases Conferences Special Reports Multimedia

Medical News
Case Studies
Clinical Review
Practice Insights
Drug Updates

Product Highlight - ENERZAIR BREEZHALER

01 Dec 2021

• The first in class LABA/LAMA/ICS triple asthma inhaler therapy available in Hong Kong.¹
• Once daily capsule with inhaler¹
• 5 min rapid onset time²
• 42% reduction in annualized rate of asthma severe exacerbations by ENERZAIR^® BREEZHALER^® (once-daily) as compared to SAL/FLU high-dose (twice-daily).²
• Breezhaler with feedback mechanism to confirm the full dosage delivery¹

ENERZAIR^® BREEZHALER^® = IND/GLY/MF 150/50/160 mcg (once-daily); SAL/FLU high-dose = SAL/FLU 50/500 mcg (twice-daily)

References:
1. Enerzair HK Prescribing Information [June 2021].
2. Kerstjens H, et al. Lancet Respir Med. 2020;8(10):1000–1012.

Wait Loading...

LOGIN TO READ FULL STORY

Editor's Recommendations

Related Diseases

Asthma

Respirology

Specialties

Multidisciplinary
Cardiology
Dermatology
Endocrinology
Gastroenterology
Hepatology
Infectious Diseases
Neurology
Obstetrics & Gynaecology
Oncology
Ophthalmology
Paediatrics
Psychiatry
Respirology
Rheumatology
Urology
Pharmacy

News

Medical News
Case Studies
Clinical Review
Practice Insights
Drug Updates

Diseases

Respirology Diseases

Conferences

Conferences Report

More Services

Drugs
Specialties
Education
Subscribe

About

MIMS Corporate
Term of Use
Privacy Policy
Feedback

Connect With MIMS

Copyright © 2024 MIMS Pte Ltd. All rights reserved.